Exicure, Inc. (XCUR) — 10-Q Filings
All 10-Q filings from Exicure, Inc.. Browse 6 Quarterly Report reports with AI-powered summaries and risk analysis.
10-Q Filings (6)
-
Exicure's Q3 Loss Widens Amid Strategic Shift, Cash Drains
— Nov 7, 2025 Risk: high
EXICURE, INC. (XCUR) reported a net loss of $2.437 million for the three months ended September 30, 2025, compared to a net loss of $1.091 million for the same -
EXICURE Acquires GPCR USA, Bets on New Therapeutics Amid Zero Revenue
— Aug 8, 2025 Risk: high
EXICURE, INC. (XCUR) reported no revenue for the three and six months ended June 30, 2025, consistent with the prior year periods. The company's net loss for th -
EXICURE Acquires GPCR Therapeutics, Bolsters Pipeline Amidst Zero Revenue
— Jun 27, 2025 Risk: high
EXICURE, INC. (XCUR) reported no revenue for the three months ended March 31, 2025, consistent with the prior year period, indicating its pre-commercial stage. -
Exicure, Inc. Files 10-Q for Q3 2024
— Nov 14, 2024 Risk: medium
Exicure, Inc. filed its 10-Q for the period ending September 30, 2024. The company, formerly known as Max-1 Acquisition Corp, is in the pharmaceutical preparati -
Exicure, Inc. Files Q2 2024 10-Q Report
— Aug 13, 2024 Risk: medium
Exicure, Inc. filed its 10-Q for the period ending June 30, 2024. The company reported financial results for the second quarter and the first six months of 2024 -
Exicure, Inc. Files Q1 2024 10-Q Report
— Jun 17, 2024 Risk: medium
Exicure, Inc. filed its quarterly report for the period ending March 31, 2024. The company, formerly known as Max-1 Acquisition Corp, is in the pharmaceutical p
Popular Companies
AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX